Pemetrexed, paclitaxel regimens equally effective in NSCLC
PointBreak trial results suggest that pemetrexed- and paclitaxel-based chemotherapy offer comparable survival outcomes and tolerability for patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) but with differing toxicity profiles.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology